3Q23 & 9M23 Performance Overview

LEVERAGE OVERVIEW OF OUR PRIVATE BUSINESSES GEORGIA CAPITAL TOTAL NET DEBT/EBITDA DEVELOPMENT OVERVIEW ➤ Despite headwinds from COVID-19, leverage profile across our private portfolio companies improved over the last 4 years. GEL MILLION 5.5x 5.3x 4.6x 3.9x 3.7x 3.7x 3.4x 3.5x 3.3x 3.3x 3.2x 3.0x 1891,039 2001,062 2251,025 268 998 258 913 255 946 238 927 244 814 245 803 242 723 248 787 248 845 Sep-221 Dec-22 Mar-23 Jun-23 Sep-232 Dec-19 Jun-20 Dec-20 Jun-21 Dec-21 Mar-22 Jun-22 Total LTM EBITDA Total Net debt -Total Net debt/EBITDA Georgia Capital PLC | General note: Figures for Hospitals, Retail (Pharmacy), Clinics and Diagnostics are given excluding IFRS 16 effects. Net debt Includes the application of the minority buyout agreement in the retail (pharmacy) business and assumes the conversion of the loans issued to our real estate and beverages businesses into equity. 1. Renewable energy business net debt, excluding US$ 10 million quasi equity. 2. LTM EBITDA excludes the gain of GEL 2.9 million from the sale of one of the polyclinics buildings in 3Q23. The net debt includes the receivable of US$ 6.2 million incurred from the sales transaction. 19

View entire presentation